Excitotoxicity

Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease

Retrieved on: 
Thursday, April 11, 2024
UNC, Doctor of Philosophy, BECN1, Autophagy, ERK, Pathology, HGF, AKT, Athira Pharma, Alzheimer's disease, Disease, Excitotoxicity, Toxicity, Shikimate pathway, ULK1

The original research article, “ Fosgonimeton Attenuates Amyloid-Beta Toxicity in Preclinical Models of Alzheimer’s Disease ,” authored by Reda, S., et al., was published in the peer-reviewed journal, Neurotherapeutics.

Key Points: 
  • The original research article, “ Fosgonimeton Attenuates Amyloid-Beta Toxicity in Preclinical Models of Alzheimer’s Disease ,” authored by Reda, S., et al., was published in the peer-reviewed journal, Neurotherapeutics.
  • “These data continue to highlight the potential of fosgonimeton as a novel therapeutic approach for Alzheimer's disease targeting multiple facets of its complex pathophysiology,” said Kevin Church, Ph.D., Chief Scientific Officer of Athira.
  • “These preclinical data published in a peer-reviewed journal suggest that fosgonimeton counteracts aspects of AD pathology that lead to neurodegeneration.
  • These findings bolster our confidence in the Phase 2/3 LIFT-AD trial evaluating fosgonimeton in mild-to-moderate AD, with data anticipated in the second half of 2024.”

Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates

Retrieved on: 
Thursday, February 22, 2024
ACT, ERP, Central nervous system, Dementia, Excitotoxicity, ALS, Research, MNDA, Pathology, Research and development, Inflammation, HGF, Conference, Society, Annual general meeting, Doctor of Philosophy, Frontiers, Biomarker, Administration, Clinical trial, Survival, Investment, Neuroprotection, Three-body problem, G&A, Athira Pharma, Lewy body, Insurance, Pharmaceutical industry

BOTHELL, Wash., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the year ended December 31, 2023, and reviewed recent pipeline and business updates.

Key Points: 
  • In December 2023, the Company announced encouraging results from the exploratory Phase 2 SHAPE clinical trial to evaluate fosgonimeton in patients with Parkinson's disease dementia and dementia with Lewy bodies.
  • In May 2023, Athira selected the 40 mg dose for further development and potential regulatory approval.
  • In January 2024, Athira completed enrollment of the LIFT-AD study, randomizing approximately 315 patients in the primary analysis population.
  • In December 2023, Athira announced encouraging results from the exploratory SHAPE Phase 2 clinical trial of fosgonimeton for the potential treatment of Parkinson's disease dementia and dementia with Lewy bodies.

FundaMental Pharma GmbH announces publication of a groundbreaking Proof-of-Concept Study in Cell Reports Medicine using a TwinF Interface Inhibitor for the Treatment of Amyotrophic Lateral Sclerosis

Retrieved on: 
Wednesday, February 7, 2024
Mortality, Heidelberg University, ALS, Research, Fundamental, NMDA, Patient, Excitotoxicity, Yan, TRPM4, Pharmaceutical industry

Heidelberg, Germany, 7 February 2024 – FundaMental Pharma GmbH (‘FundaMental’ or ’the Company’), a neuroscience company developing first-in-class small molecule inhibitors for treatment of a range of neurodegenerative diseases, today announces the publication of a groundbreaking study by Neurobiologists in Heidelberg using FundaMental Pharma’s small molecule TwinF interface inhibitor, FP802.

Key Points: 
  • Heidelberg, Germany, 7 February 2024 – FundaMental Pharma GmbH (‘FundaMental’ or ’the Company’), a neuroscience company developing first-in-class small molecule inhibitors for treatment of a range of neurodegenerative diseases, today announces the publication of a groundbreaking study by Neurobiologists in Heidelberg using FundaMental Pharma’s small molecule TwinF interface inhibitor, FP802.
  • The study provides seminal preclinical proof-of-concept data for the treatment of amyotrophic lateral sclerosis (ALS).
  • Most importantly, the validated ALS clinical biomarker neurofilament light chain (Nf-L) was reduced in line with the positive treatment effects.
  • TwinF interface inhibitors constitute an entirely new class of drugs that safely ameliorate glutamate neurotoxicity, a common cause of neurodegeneration.

Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates

Retrieved on: 
Thursday, November 9, 2023
ACT, Walter, Investment, Neuromuscular junction, Patient, Pathology, Conference, Cognition, R, ADAS, Inflammation, AFL, Society, Glial fibrillary acidic protein, Food, Toxicity, HGF, IND, Administration, GFAP, Excitotoxicity, Alzheimer's disease, G&A, Microglia, Communication, Neuroinflammation, Athira Pharma, Research and development, Brain cell, Biomarker, Riluzole, ALS, Frontotemporal dementia, Washington Convention Center, Drug development, AAIC, Enzyme inhibitor, Plasma, Mouse, Doctor of Philosophy, FDA, Neurodegenerative disease, Survival, Central nervous system, GST, Fine chemical, Pharmaceutical industry, Medical imaging, Cryptocurrency, Neuroscience, Athira

BOTHELL, Wash., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended September 30, 2023, and provided pipeline and business updates.

Key Points: 
  • BOTHELL, Wash., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the quarter ended September 30, 2023, and provided pipeline and business updates.
  • R&D expenses were $27.2 million for the quarter ended September 30, 2023, compared with $17.0 million for the quarter ended September 30, 2022.
  • G&A expenses were $7.8 million for the quarter ended September 30, 2023, compared with $7.2 million for the quarter ended September 30, 2022.
  • The increase was primarily due to increases in personnel expenses, partially offset by a decrease in business development expenses.

Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)

Retrieved on: 
Thursday, October 5, 2023
ALS, Asian literature, Neuromuscular junction, Plasma, Excitotoxicity, Brain cell, Poster, Mouse, AFL, HGF, Athira Pharma, Riluzole, Pharmaceutical industry

BOTHELL, Wash., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, presented new preclinical data supporting the potential benefit of ATH-1105 for the treatment of amyotrophic lateral sclerosis (ALS) at the 22nd Annual Northeast ALS Consortium (NEALS) Meeting, taking place October 4-6, 2023, virtually and in-person in Clearwater, Florida. ATH-1105 is an orally administered small molecule therapeutic candidate designed to enhance the neurotrophic hepatocyte growth factor (HGF) system.

Key Points: 
  • ATH-1105 is an orally administered small molecule therapeutic candidate designed to enhance the neurotrophic hepatocyte growth factor (HGF) system.
  • “There is an urgent need for new ALS treatment options, particularly those aimed at stopping or slowing neurodegeneration.
  • We are encouraged by the consistent benefit of ATH-1105 in these animal models, whether given pre- or post-symptom onset or in combination with riluzole.
  • NEALS is a closed meeting, and the presentation will be available on the Scientific Publications & Presentations page of the company’s website at w ww.at hira.com .

Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting

Retrieved on: 
Tuesday, April 25, 2023
ACT, Molecule, Athira Pharma, Cognition, HGF, Enzyme inhibitor, GFAP, AFL, AAN, CFB, Survival, Deficit spending, American Academy, Donepezil, Biomarker, Inflammation, Bangladesh Technical Education Board, Model, Plasma, St. Kevin's Church, Camden Row, Dublin, Oxidative stress, Hepatocyte growth factor, Patient, AKT, Neuroprotection, Amyotrophy, Annual general meeting, American Academy of Neurology, ALS, IND, MMSE, Dopaminergic, Neurotoxicity, Excitotoxicity, Neuroinflammation, Pharmaceutical industry, Management, Medical imaging, Medical device, Aroma compound, Neurotrophic factors

BOTHELL, Wash., April 25, 2023 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the presentation of new data from its small molecule programs enhancing the HGF/MET neurotrophic system. The data were presented in oral and poster presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting taking place from April 22-27, 2023, in person in Boston, Mass. and virtually.

Key Points: 
  • The data were presented in oral and poster presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting taking place from April 22-27, 2023, in person in Boston, Mass.
  • “These and other data presented at this year’s AAN Annual Meeting further support other previously reported post hoc findings from ACT-AD that showed improvements in plasma biomarkers and measures of cognition.
  • Additionally, we reported new data that further elucidate the interaction between fosgonimeton and AChEIs.
  • The information presented in this press release is solely the responsibility of Athira and does not necessarily represent the official views of the National Institutes of Health.

Gene therapy candidate for amyotrophic lateral sclerosis (ALS) demonstrates bioactivities in a murine model of the disease

Retrieved on: 
Monday, March 13, 2023
Friedreich's ataxia, Respiratory failure, CNS, Muscular dystrophy, Animal, Cell, Sporadic group, Spinal cord, Atrophy, SOD1, Excitotoxicity, OTC, LEAS, ALS, Multiple sclerosis, Gene, AAV, Death, Nervous system, Brain cell, Oxidative stress, Rare, RNA, Risk, Muscle atrophy, Multimedia, European Society of Gene and Cell Therapy, Facial muscles, DNA, Myasthenia gravis, Denervation, DSM-IV codes, Diagnosis, Neuropathology, Tetraplegia, Messenger, Nerve, Drug Quality and Security Act, Therapy, The Company, Human, FINRA, Cancer, Motor cortex, Survival, Patient, Vaccine, Dietary supplement

Thus, long-term supplementation of the s-KL protein via gene therapy technology is an attract new measure for treatment of this deadly disease.

Key Points: 
  • Thus, long-term supplementation of the s-KL protein via gene therapy technology is an attract new measure for treatment of this deadly disease.
  • The technology was licensed on an exclusive worldwide basis from the Universitat Autonomo de Barcelona in Barcelona, Spain.
  • The overexpression of the SOD1 gene in humans is called "familial ALS" and occurs in 5%-10% of all ALS cases.
  • The delivery and expression of the s-KL protein by the s-KL gene may be an effective therapy in this degenerative neuromuscular disease" said Dr. Sinkule.

Algernon NeuroScience Initiates Traumatic Brain Injury Research Program With DMT; Appoints Global TBI Expert as Advisor

Retrieved on: 
Tuesday, February 21, 2023
Accident, Brain, Glasgow Coma Scale, Excitotoxicity, Tropomyosin receptor kinase B, Messenger, Human, Trial of the century, TBI, BDNF, AGN, Patient, DMT, Traumatic brain injury, Stroke, Vehicle registration plates of Nepal, N,N-Dimethyltryptamine, CSE, Reactive oxygen species, Nursing, Pharmaceutical industry

AGN Neuro has an active stroke research program underway and is currently conducting a Phase 1 DMT study in the Netherlands at the Centre for Human Drug Research.

Key Points: 
  • AGN Neuro has an active stroke research program underway and is currently conducting a Phase 1 DMT study in the Netherlands at the Centre for Human Drug Research.
  • AGN Neuro, in consultation with its TBI advisors, may plan and conduct certain preclinical research to help better guide the planned Phase 2 clinical study.
  • DMT is an agonist of sigma-1, a part of the body’s natural defense against physiological stresses, which is elevated following TBI.
  • AGN Neuro is also pleased to announce that it has appointed global TBI expert Dr. Andrew Maas as a scientific and medical advisor to help guide its TBI research program.

Avirmax Biopharma Inc. Will Present at Glaucoma 360 New Horizons Forum 2023

Retrieved on: 
Friday, February 3, 2023
Rat, Detection, DARC, Excitotoxicity, Mouse, Therapy, Glaucoma, Westin St. Francis, Rita Raave, ABI, NMDA, Patient, Chief scientific officer, CMC, Research, IOP, Death, FDA, RGC, Paratriathlon, Pont, Pharmaceutical industry

HAYWARD, Calif., Feb. 3, 2023 /PRNewswire/ -- Avirmax Biopharma Inc. (ABI), Chief Executive and Scientific Officer, Shengjiang Shawn Liu will present the Avirmax BioPharma Inc (ABI)'s progress in the innovation and development of genetic medicines for glaucoma treatment at Glaucoma 360 New Horizons Forum at The Westin St. Francis in San Francisco, Feb 03, 2023.

Key Points: 
  • HAYWARD, Calif., Feb. 3, 2023 /PRNewswire/ -- Avirmax Biopharma Inc. (ABI), Chief Executive and Scientific Officer, Shengjiang Shawn Liu will present the Avirmax BioPharma Inc (ABI)'s progress in the innovation and development of genetic medicines for glaucoma treatment at Glaucoma 360 New Horizons Forum at The Westin St. Francis in San Francisco, Feb 03, 2023.
  • Since its founding, Avirmax Biopharma Inc (ABI) has been focusing on developing an effective gene therapy product, ABI-902 for glaucoma treatment.
  • ABI-902 is manufactured by Avirmax CMC Inc.
    Now in its 12th year, the Glaucoma 360 New Horizons Forum unites key clinical, industrial, financial, and FDA leaders in a unique exchange on research innovation and advances in glaucoma treatment.
  • Avirmax Biopharma Inc. (ABI) is a subsidiary of Avirmax Inc., a San Francisco Bay Area based company working on genetic medicine.

Medical Marijuana, Inc. Participates in Preclinical Research Study on Therapeutic Benefits of CBD on Traumatic Brain Injuries

Retrieved on: 
Monday, February 6, 2023
Research, Medical cannabis, Neuron, Excitotoxicity, Parkinson's disease, OTC, Glutamic acid, Cannabidiol, Central nervous system, Brain damage, Cerebral cortex, Patient, SAN, El Siglo, Medical Marijuana, Inc., THC, Mortality, Death, Pharmaceutical industry, Vaccine, CBD

SAN DIEGO, CA, Feb. 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire –  Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands, and supply chain, announced today that its subsidiary HempMeds® recently took part in a collaboration on a study to demonstrate the effectiveness of hemp-based cannabidiol (CBD) in the treatment of Parkinson's Disease.  The Company is also collaborating with the Center for Research and Advanced Studies of Neurological Diseases at the Siglo XXI National Medical Center, on a preclinical study in an animal model that demonstrated the ability to decrease extracellular glutamate levels that can lead to traumatic brain injuries.

Key Points: 
  • The Company is also collaborating with the Center for Research and Advanced Studies of Neurological Diseases at the Siglo XXI National Medical Center, on a preclinical study in an animal model that demonstrated the ability to decrease extracellular glutamate levels that can lead to traumatic brain injuries.
  • In this study, it was also shown that the application of CBD helps sensorimotor improvement,” Dr. Rocha stated.
  • Dr. Rocha added: “The results obtained in this study help to understand how the oral application of cannabidiol reduces excitotoxicity caused by long-term traumatic brain injuries and facilitates functional recovery.
  • HempMeds' commitment is to free access around the globe enabling people worldwide everyday to obtain the health benefits of cannabis-based products in an easy way.